Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT06539468 · Skin Basal Cell Carcinoma
NCT05278208 · High Grade Glioma, Meningioma, and more
NCT05651828 · Advanced Basal Cell Carcinoma
Novartis Investigative Site
Hong Kong
Novartis Investigative Site
Nagoya, Aichi-ken
Novartis Investigative Site
Kobe, Hyōgo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions